LONDON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Mr. Peter Rands disposed of an aggregate of 1,532,001 common shares in the capital of Small Pharma Inc. (the “Company”) between September 25, 2023 and September 27, 2023 at an average price of $0.177 per common share for aggregate proceeds of $284,199.177.
Prior to the disposition, and as at the date of his last early warning report, Mr. Rands, together with any joint actor, beneficially owned or exercised control or direction over, directly or indirectly, 91,117,974 common shares of the Company, representing approximately 28.76% of the issued and outstanding common shares of the Company. Following the disposition, Mr. Rands, together with any joint actor, beneficially owned or exercised control or direction over, directly or indirectly, 83,799,723 common shares of the Company, representing approximately 26.1% of the issued and outstanding common shares of the Company.
The common shares of the Company are held for investment purposes. Mr. Rands and any joint actor may increase or decrease its investment, directly or indirectly, in securities of the Company from time to time, depending on the trading price of the common shares, market conditions or any other relevant factors.
Small Pharma Inc. is located at 50 Featherstone St., 1st Floor, London, EC1Y 8RT, United Kingdom. The Acquirer is located at 40 Bloemfontein Road, London, W12 7BX. A copy of the early warning report to which this news release relates can be obtained on the SEDAR profile of Small Pharma at www.sedar.com. For further information please contact Peter Rands. Phone: +44(0)7812 121944.
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDARplus.ca for important risk disclosures. It’s your money and your responsibility.